US 8287857
Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
granted A61KA61K2039/515A61K2239/31
Quick answer
US patent 8287857 (Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Oct 16 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 26
- CPC classes
- A61K, A61K2039/515, A61K2239/31, A61K2239/38, A61K2239/57